| Literature DB >> 25758269 |
Pei-Yuan He, Yue-Jin Yang1, Shu-Bin Qiao, Bo Xu, Min Yao, Yong-Jian Wu, Jin-Qing Yuan, Jue Chen, Hai-Bo Liu, Jun Dai, Xin-Ran Tang, Yang Wang, Wei Li, Run-Lin Gao.
Abstract
BACKGROUND: Percutaneous coronary intervention (PCI) through transradial approach (TRA) has shown to be safe and effective as transfemoral approach (TFA) among unselected patients. However, very few studies have compared the outcomes between TRA and TFA specifically in patients with a history of coronary artery bypass grafting surgery (CABG).Entities:
Mesh:
Year: 2015 PMID: 25758269 PMCID: PMC4833979 DOI: 10.4103/0366-6999.152488
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Baseline characteristics
| Variable | TRA ( | TFA ( | |
|---|---|---|---|
| Age (years) | 62.76 ± 9.16 | 62.75 ± 9.47 | 0.9935 |
| Age ≥ 80 years | 112 (99.1) | 285 (97.9) | 0.3849 |
| Male | 91 (80.5) | 232 (79.7) | 0.8556 |
| Prior MI, | 46 ( 40.7) | 129 (44.3) | 0.5089 |
| Prior PCI, | 36 (31.9) | 74 (25.4) | 0.1969 |
| Prior stroke, | 9 (8.0) | 10 (3.4) | 0.0658 |
| Diabetes, | 41 (36.3) | 85 (29.2) | 0.1718 |
| Hypertension, | 84 (74.3) | 182 (62.5) | 0.0227 |
| Hyperlipidemia, | 75 (66.4) | 154 (52.9) | 0.0136 |
| Diagnosis, | |||
| STEMI | 5 (4.4) | 11 (3.8) | 0.7680 |
| NSTEMI | 8 (7.1) | 12 (4.1) | 0.2190 |
| Unstable angina | 69 (61.1) | 168 (57.7) | 0.5421 |
| Stable angina | 30 (26.5) | 88 (30.2) | 0.4642 |
| LVEF (%) | 58.69 ± 7.34 | 58.46 ± 7.92 | 0.7926 |
| LVEF < 50% | 11 (9.8) | 33 (11.8) | 0.5733 |
| Hemoglobin (g/L) | 137.39 ± 13.64 | 137.44 ± 14.83 | 0.9788 |
| Peri-procedural medication, | |||
| GP IIb/IIIa inhibitor | 6 (5.3) | 9 (3.1) | 0.3066 |
| Warfarin | 1 (0.9) | 5 (1.7) | 0.5130 |
| LMWH | 90 (79.6) | 224 (77.0) | 0.5601 |
| Fondaparinux | 2 (1.8) | 5 (1.7) | 0.9715 |
Data represented as n (%) or mean ± SD. GP IIb/IIIa inhibitor: Glycoprotein IIb/IIIa inhibitor; LMWH: Low weight molecule heparin; LVEF: Left ventricular ejection fraction; MI: Myocardial infarction; NSTEMI: Non-ST-segment elevation myocardial infarction; PCI: Percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; TFA: Transfemoral approach; TRA: Transradial approach; SD: Standard deviation.
Angiographic characteristics and procedure outcomes
| Variable | TRA ( | TFA ( | |
|---|---|---|---|
| Graft | |||
| Number of grafts | 2.42 ± 0.83 | 2.55 ± 0.83 | 0.1453 |
| IMA graft, | 95 (84.1) | 258 (88.7) | 0.2217 |
| SVG graft, | 99 (87.6) | 261 (89.7) | 0.5515 |
| Graft stenosis, | 85 (75.2) | 225 (77.3) | 0.6556 |
| Intervention, | |||
| Native vessel | 84 (75.0) | 211 (73.0) | 0.7103 |
| Graft | 24 (21.4) | 69 (23.9) | 0.5958 |
| Native vessel + graft | 4 (3.6) | 9 (3.1) | 0.8191 |
| Device | |||
| Sheath size | 6.03 ± 0.28 | 6.07 ± 0.47 | 0.3114 |
| Sheath size ≥ 7F, | 6 (5.3) | 25 (8.6) | 0.2497 |
| DES, | 111 (98.2) | 288 (99.0) | 0.5604 |
| Number of stent | 1.95 ± 1.14 | 1.79 ± 0.98 | 0.2103 |
| Stent diameter (mm) | 3.13 ± 0.56 | 3.04 ± 0.56 | 0.0488 |
| Total length of stent (mm) | 43.79 ± 30.69 | 42.47 ± 28.82 | 0.6864 |
| IABP support | 2 (1.8) | 4 (1.4) | 0.7720 |
Data represented as n (%) or mean ± SD. IMA: Internal mammary artery; LM: Left main disease; IABP: Intra-aortic balloon pump; SVG: Saphenous vein graft; TFA: Transfemoral approach; TIMI: Thrombolysis in myocardial infarction; TRA: Transradial approach; SD: Standard deviation; DES: Drug-eluting stent.
Short- and medium-term clinical outcomes
| Variables | TRA ( | TFA ( | |
|---|---|---|---|
| Angiographic success | 110 (97.4) | 291 (100) | 0.0210 |
| Procedure success | 112 (99.1) | 285 (97.9) | 0.6791 |
| In-hospital outcomes | |||
| NACE | 3 (2.7) | 8 (2.7) | 1.0000 |
| All-cause death | 0 (0.0) | 1 (0.3) | 1.0000 |
| MI | 1 (0.9) | 3 (1.0) | 1.0000 |
| Stroke | 0 (0.0) | 0 (0.0) | 1.0000 |
| Repeat revascularization | 0 (0.0) | 2 (0.7) | 1.0000 |
| BARC ≥ 2 grade bleeding | 10 (8.8) | 54 (18.6) | 0.0118 |
| Access site related bleeding | 8 (7.1) | 40 (13.7) | 0.0517 |
| Access site complications | 8 (7.1) | 32 (11.0) | 0.2226 |
| Total hospital stay | 7 (5,10) | 7 (5, 9) | 0.6253 |
| Postprocedure stay | 3 (2,4) | 3 (2, 5) | 0.0256 |
| One-year outcomes | |||
| MACE | 13 (11.5) | 35 (12.0) | 0.8837 |
| All-cause death | 2 (1.8) | 3 (1.0) | 0.6220 |
| MI | 4 (3.5) | 6 (2.1) | 0.4757 |
| Repeat revascularization | 13 (11.5) | 28 (9.6) | 0.8103 |
Data represented as n (%) or mean ± SD. BARC: Bleeding Academic Research Consortium; MACE: Major adverse cardiovascular event; MI: Myocardial infarction; NACE: Net adverse clinical events; TFA: Transfemoral approach; TRA: Transradial approach; SD: Standard deviation.
Figure 1(a) Curves for time to major adverse cardiovascular events according to transradial or transfemoral approach at 12 months of follow-up; (b) Curves for time to death according to transradial or transfemoral approach at 12 months of follow-up; (c) Curves for time to MI according to transradial or transfemoral approach at 12 months of follow-up; (d) Curves for time to repeat revascularization according to transradial or transfemoral approach at 12 months of follow-up. MI: Myocardial infarction; TFA: Transfemoral approach; TRA: Transradial approach.
Outcomes for patients undergoing graft intervention
| Variable | TRA ( | TFA ( | |
|---|---|---|---|
| Procedure success | 28 (100) | 77 (98.7) | 1.0000 |
| Procedure time (min) | 25 (16, 39) | 27.5 (15, 40) | 0.5271 |
| Access site complications | 2 (7.1) | 6 (7.7) | 1.0000 |
| In-hospital NACE | 0 (0) | 0 (0) | 1.0000 |
| 1-year MACE | 6 (21.4) | 8 (10.3) | 0.1904 |
Data represented as n (%) or median (interquartile range). MACE: Major adverse cardiovascular event; NACE: Net adverse clinical event; TRA: Transradial approach; TFA: Transfemoral approach.
Multivariable regression analysis
| Outcomes | ||
|---|---|---|
| In-hospital outcomes | ||
| NACE | 0.83 (0.17–4.10) | 0.8214 |
| Access site complications | 1.67 (0.71–3.93) | 0.2375 |
| BARC ≥ 2 grade bleeding | 2.41 (1.14–5.10) | 0.0216 |
| One-year outcomes | ||
| MACE | 1.01 (0.80–1.27) | 0.9355 |
BARC: Bleeding Academic Research Consortium; CI: Confidence interval; MACE: Major adverse cardiovascular event; NACE: Net adverse clinical event; HR: Hazard ratio.